Thu, Jul 24, 2014, 3:54 AM EDT - U.S. Markets open in 5 hrs 36 mins

Recent

% | $
Click the to save as a favorite.

MiMedx Group, Inc. Message Board

  • pacorabon69 pacorabon69 Nov 26, 2013 12:08 PM Flag

    News

    We could announce an $8 billion share buy back and this stock wouldn't move
    Like watching paint dry IMHO
    MARIETTA, Ga., Nov. 26, 2013 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the summaries of a selection of the seven posters highlighting MiMedx allografts presented at the recent 10th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona.

    The posters chronicled the clinical effectiveness of the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts and detailed a wide range of wounds and injuries with varying degrees of etiologies. A sampling of the posters presenting dHACM cases and studies, along with a summary of the respective study results and conclusions are as follows:
    •EpiFix Utilization for Advanced Wound Therapy in an Evidence Based Approach to Treat Foot Ulcers.•Results: 10 non-healing diabetic foot ulcers (DFUs) and 3 pressure ulcers were treated with EpiFix®. 75% of the ulcers healed with EpiFix® at an average healing time of 11.7 weeks after 3.5 applications. Complete healing occurred in 67% of the DFUs and 100% of pressure ulcers. Of the 3 DFUs not healing 100%, 2 were non-compliant and one had foot deformity issues prior to the study causing discontinuation of the graft.
    •Conclusion: Multiple advantages were noted in using EpiFix® to treat non-healing wounds in the VA clinic setting including ease of use and availability of multiple graft sizes to minimize waste. With adequate wound debridement and proper wound bed maintenance, a 75% healing rate of non-healing foot ulcers was achieved with the utilization of EpiFix®.

    •Dehydrated Human Amnion/Chorion Membrane for the Treatment of Full-Thickness Plantar Burn in a Diabetic Patient: A Case Report.•Results: Rapid healing of wound occurred with epithelialization essentially complete 4 weeks after dHACM application.
    •Conclusion: This case report demonstrated that dHACM can be used as an effective treatment for plantar burns in diabetics and deserves further study.

    •Treatment of Lower Extremity Chronic Wounds with Dehydrated Human Amnion/Chorion Membrane (dHACM): A Vascular Compromised Cohort (ABI

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MDXG
6.65+0.08(+1.22%)Jul 23 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Xilinx Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT